Dr Delese Mimi Darko, the chief executive officer of the Food and Drugs Authority (FDA) has said that the new malaria vaccine approved by Ghana has the potential of dealing with all forms of malaria parasites.
Darko’s comment is in reference to the discovery of a new invasive mosquito species said to be deadlier than the traditional anopheles mosquitoes which transmits malaria.
Speaking to sit-in host of the Asaase Breakfast Show, Benjamin Offei-Addo on Friday (14 April), Darko said “This vaccine will prevent a new strain, so it will deal with all other strain.”
Watch the interview below:
Approval
Ghana is the first country to approve a new malaria vaccine that has been described as a “world-changer” by the scientists who developed it.
The vaccine – called R21 – appears to be hugely effective, in stark contrast to previous ventures in the same field.
Ghana’s drug regulators have assessed the final trial data on the vaccine’s safety and effectiveness, which is not yet public, and have decided to use it.
The World Health Organization is also considering approving the vaccine.
Malaria kills about 620,000 people each year, most of them young children.
It has been a massive, century-long, scientific undertaking to develop a vaccine that protects the body from the malaria parasite.
Trial data from preliminary studies in Burkina Faso showed the R21 vaccine was up to 80% effective when given as three initial doses, and a booster a year later.
New malaria vaccine is world-changing, say scientists. But widespread use of the vaccine hinges on the results of a larger trial involving nearly 5,000 children.
These had been expected to take place at the end of last year, but have still not been formally published.
However, they have been shared with some government bodies in Africa, and scientists.
Ghana’s Food and Drugs Authority, which has seen the data, has approved the vaccine’s use in children aged between five months to three years old.
Other African countries are also studying the data, as is the World Health Organization (WHO).
Prof Adrian Hill, director of the Jenner Institute at the University of Oxford, where the vaccine was invented, says African countries are declaring: “we’ll decide”, after being left behind in the rollout of COVID-19 vaccines during the pandemic.
“We expect R21 to make a major impact on malaria mortality in children in the coming years, and in the longer term [it] will contribute to overall final goal of malaria eradication and elimination,” he said.
The Serum Institute of India is preparing to produce between 100-200 million doses per year, with a vaccine factory being constructed in Accra, Ghana.
Each dose of R21 is expected to cost a couple of dollars.
Adar Poonawalla, CEO of the Serum Institute, said: “Developing a vaccine to greatly impact this huge disease burden has been extraordinarily difficult.”
He added that Ghana, as the first country to approve the vaccine, represents a “significant milestone in our efforts to combat malaria around the world”.
Reporting by Fred Dzakpata in Accra
Asaase Radio 99.5 broadcasts on radio via 99.5 in Accra, 98.5 in Kumasi, 99.7 in Tamale, 100.3 in Cape Coast and on our affiliates Bawku FM 101.5 in Bawku, Beats FM 99.9 in Bimbilla, Somua FM 89.9 in Gushegu, Stone City 90.7 in Ho, Mining City 89.5 in Tarkwa and Wale FM 106.9 in Walewale
Tune in or log on to broadcasts online: www.asaaseradio.com, Sound Garden and TuneIn
Follow us on Twitter: @asaaseradio995
Live streaming: facebook.com/asaaseradio99.5. Also on YouTube: Asaase Radio Official.
Join the conversation. Call: 020 000 9951 or 059 415 7777. Or WhatsApp: 020 000 0995.
#AsaaseRadio
#TheVoiceofOurLand
